Molecular inhibition of HIV type 1 by HIV type 2: Effectiveness in peripheral blood mononuclear cells

AIDS Research and Human Retroviruses

Volumn 14, Issue 1, 1998, Pages 59-64

  Al Harthi, Lena ^a,b   Owais, Mohammad ^a   Arya, Suresh K ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE TRANSFER; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LONG TERMINAL REPEAT; MONONUCLEAR CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROVIRUS; VIRUS TRANSCRIPTION;

EID: 0031984492     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.59     Document Type: Article

References (44)

1. SM) closely related to HIV-2. Nature (London) 1989;339:389-392.
2. Huet T, Cheynier R, Meyerhans A, Roelants G, and Wain-Hobson S: Genetic organization of a chimpanzee lentivinis related to HIV-1. Nature (London) 1990;345:356-359.
3. SM-related HIV-2 in West Africa. Nature (London) 1992;358:495-499.
4. Robertson DL, Hahn BH, and Sharp PM: Recombination in AIDS viruses. J Mol Evol 1995;40:249-259.
5. Kanki PJ, M'Boup S, Ricard D, Barin F, Romet-Lemonne JL, Denis F, Boye C, Sangare L, Travers K, Albaum M, Marlink R, and Essex ME: Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa. Science 1987;236:827-831.
6. Marlink RG, Ricard D, M'Boup S, Kanki PJ, Romet-Lemonne JL, N'Doye I, Diop K, Simpson MA, Greco F, Chou MJ, and Essex ME: Clinical, hematologic, and immunologic cross-sectional evaluation of individuals exposed to human immunodeficiency virus type-2 (HIV-2). AIDS Res Hum Retroviruses 1988;4:137-148.
7. DeCock KM and Brun-Vezinet F: Epidemiology of HIV-2 infection. AIDS 1989;3:S89-95.
8. Grez M, Dietrich U, Balfe P, von Briesen H, Maniar JK, Mahambre G, Delwart EL, Mullins JI, and Rubsamen-Waigmann H: Genetic analysis of HIV type 1 and 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. J Virol 1994;68: 2161-2168.
9. Andreasson PA, Dias F, Naucler A, Andersson S, and Biberfeld G: A perspective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 1993;7:989-993.
10. Kanki PJ, Travers KU, M'Boup S, Hsieh C, Marlink RG, Gueye-Ndiaye A, Siby T, Thior I, Hernandez-Avila M, Sankale JL, Ndoye I, and Essex ME: Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343:943-946.
11. Pepin J, Morgan G, Dunn D, Gevao S, Mendy M, Gaye I, Scollen N, Tidder R, and Whittle H: HIV-2 induced immunosuppression among asymptomatic West African prostitutes: Evidence that HIV-2 is pathogenic, but less so than HIV-1. AIDS 1991;5:1165-1172.
12. Marlink R, Kanki PJ, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, and Gueye EH: Reduced rate of disease development after HIV-2 infection compared to HIV-1. Science 1994;265:1587-1590.
13. Travers K, Mboup S, Marlink R, Gueye-Ndiaye A, Siby T, Thior I, Traore I, Dieng-Sarr A, Sankale JL, Mullins S, Ndoye I, Hsieh CC, Essex ME, and Kanki PJ: Natural protection against HIV-1 infection provided by HIV-2. Science 1995;268:1612-1615.
14. Putkonen P, Walther L, Zhang YJ, Li SL, Nilsson C, Albert J, Biberfeld P, Thorstensson R, and Biberfeld G: Long term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nature Med 1995;9:914-918.
15. Abimiku AG, Franchini G, Tartaglia J, Aldrich K, Myagkikh M, Markham PD, Chong P, Klein M, Kieny MP, Paoletti E, Gallo RC, and Robert-Guroff M: HIV-1 recombinant poxvirus vaccine induces cross protection against HIV-2 challenge in rhesus macaques. Nature Med 1995;321-329.
16. Arya SK, Zamani M, and Gallo RC: HIV-2 inhibits HIV-1. AIDS Res Hum Retroviruses 1994;10:5158.
17. Arya SK and Gallo RC: Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV-1: A new approach to gene therapy for HIV infection. Proc Natl Acad Sci USA 1996;93: 4486-4491.
18. Arya SK: Human and simian immunodeficiency retroviruses: Activation and differential transactivation of gene expression. AIDS Res Hum Retroviruses 1988;4:175-186.
19. Arya SK, Beaver B, Jagodzinski L, Ensoli B, Kanki PJ, Albert J, Fenyö EM, Biberfeld G, Zagury JG, Laure F, Essex M, Norrby E, Wong-Staal F, and Gallo RC; New human and simian HIV related retroviruses possess functional transactivator (tat) gene. Nature (London) 1987;328:548-550.
20. Arya SK: Human immunodeficiency virus type 2 (HIV-2) transactivator (Tat): Functional domains and the search for transdominant negative mutants. AIDS Res Hum Retroviruses 1993;9: 839-848.
21. Rappaport J, Arya SK, Richardson MW, Baier-Bitterlich G, and Klotman PE: Inhibition of HIV-1 expression by HIV-2. J Mol Med 1995;73:583-589.
22. Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, and Wong-Staal F: Molecular characterization of human T cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science 1984;226:1165-1171.
23. Kumar P, Hui HX, Kappes C, Haggarty BS, Hoxie JA, Arya SK, Shaw GM, and Hahn BH: Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate. J Virol 1990;64:890-901.
24. Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, and Srinivasan A: An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency syndrome type 1. J Virol 1992;66:7515-7521.
25. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, and Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59: 284-291.
26. Naidu YM, Kestler HW, Li Y, Butler CV, Silva DP, Schmidt DK, Troup CD, Sehgal PK, Sonigo P, and Daniel MD: Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: Persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol 1988;62:4691-4696.
27. Goa F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, Neequaye AE, Whelam TM, Ho DD, Shaw GM, Sharp PM, and Hahn BH: Genetic diversity of human immunodeficiency virus type 2: Evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994;66:7433-7447.
28. Thierry AR, Rabinovich P, Peng B, Mahan LC, Bryant JL, and Gallo RC: Characterization of liposome-mediated gene delivery: Expression, stability and pharmacokinetics of plasmid DNA. Gene Ther 1997;4:226-237.
29. Chowdhury IH, Chao W, Potash MJ, Sova P, Gendelman HE, and Volsky DJ: Vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J Virol 1996;70:5336-5345.
30. Camaur D and Trono D: Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol 1996; 70:6106-6111.
31. Simon JH, Fouchier RA, Southerling TE, Guerra CB, Grant CK, and Malim MH: The Vif and Gag proteins of human immunodeficiency virus type 1 colocalizes in infected human T cells. J Virol 1997;71:5259-5267.
32. Hart AR and Cloyd MW: Interference patterns of human immunodeficiency viruses HIV-1 and HIV-2. Virology 1990;177:1-10.
33. Guern ML and Levy JA: Human immunodeficiency virus (HIV) type 1 can superinfect HIV-2 infected cells: Pseudotype virions produced with expanded cellular host range. Proc Natl Acad Sci USA 1992;89:363-367.
34. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane G-protein-coupled receptor. Science 1996;272:872-877.
35. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Marzio PD, Marmon S, Sutton Re, Hill CM, Davis CB, Peiper SC, Schall TJ, Litman DR, and Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 1996;381:661-666.
36. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673.
37. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, and Sodroski J: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148.
38. Deng H, Unutmaz D, Kewalramani VN, and Littman DR: Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (London) 1997;388:296-300.
39. Arya SK and Gallo RC: Human immunodeficiency virus type 2 long terminal repeat: Analysis of regulatory elements. Proc Natl Acad Sci USA 1988;85:9753-9757.
40. Evans LA, Moreau J, Odehouri K, Seto D, Thomson Honnebier G, Legg H, Barboza A, Cheng-Mayer C, and Levy JA: Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient. Lancet 1988;2:1389-1391.
41. George JR, Ou CY, Parekh B, Brattegaard K, Brown V, Boateng E, and De Cock KM: Prevalence of HIV-1 and HIV-2 mixed infections in Cote d'Ivoire. Lancet 1992;340:337-339.
42. Peeters M, Gershy-Damet GM, Fransen K, Koffi K, Coulibaly M, Delaporte E, Piot P, and van der Groen G: Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Cote d'Ivoire. Lancet 1992;340:339-340.
43. Garzino-Demo A, Gallo RC, and Arya SK: Human immunodeficiency virus type 2 (HIV-2): Packaging signal and associated novel regulatory element. Hum Gene Ther 1995;6:177-184.
44. Arya SK and Gallo RC: Advances in genetics: Gene therapy. In One World: The Health and Survival of the Human Species in the 21st Century (Lanza R, ed.). Health Press, Santa Fe, New Mexico, 1996, pp. 49-57.